KIMS · NSE
Krishna Institute of Medical Sciences Limited
₹795.6
+3.62% (+₹27.8)
Prev. close
₹767.8
Volume
10,43,606
Delivery %
56.5%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on KIMS with a target of Rs 877; strong bullish structure, positive trend alignment, and increased volume partic…” | Virat JagadBonanza Portfolio | Krishna Institute of Medical Sciences | PENDING | |
| “Recommends buying Krishna Institute of Medical Sciences (KIMS) with a target price of ₹840. The call implies a bullish o…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Krishna Institute of Medical Sciences | HIT | |
| “Recommends buying Krishna Institute of Medical Sciences Ltd. (KIMS) at ₹720–740, targeting ₹830 in two to three months w…” | Marketsmith India AnalysisMarketsmith India | Krishna Institute of Medical Sciences Ltd. | MISS | |
| “Bullish on Krishna Institute Of Medical Sciences, recommending a buy at ₹735 with a target of ₹790 and a stop loss at ₹7…” | Sumeet BagadiaChoice Equity Broking | Krishna Institute of Medical Sciences Limited | MISS | |
| “Recommends buying Krishna Institute Of Medical Sciencs at ₹727, targeting ₹780, with a stop loss at ₹700, as a breakout …” | Sumeet BagadiaChoice Equity Broking | Krishna Institute Of Medical Sciences | MISS | |
| “Recommends buying Krishna Institute Of Medical Sciences at ₹713, targeting ₹770, with a stop loss at ₹688, based on a br…” | Sumeet BagadiaChoice Equity Broking | Krishna Institute Of Medical Sciences | MISS | |
| “Bullish on Krishna Institute Of Medical Sciencs, advising a buy at ₹722 with a target of ₹777 and a stop loss at ₹700. T…” | Sumeet BagadiaChoice Equity Broking | Krishna Institute Of Medical Sciencs | MISS | |
| “Bullish on KIMS Hospitals; recommends buying above ₹765 and on dips to ₹740, with a stop loss at ₹725 and a target of ₹8…” | Raja VenkatramanNeoTrader | Krishna Institute of Medical Sciences Ltd | MISS | |
| “Prabhudas Lilladher recommends buying Krishna Institute of Medical Sciences (KIMS) with a target price of ₹815. The call…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Krishna Institute of Medical Sciences | HIT | |
| “Recommends buying Krishna Institute of Medical Sciences Ltd (KIMS) around ₹761.25, setting a stop loss at ₹734 for a tar…” | Sumeet BagadiaChoice Equity Broking | Krishna Institute of Medical Sciences Ltd | MISS | |
| “Recommends buying Krishna Institute of Medical Sciences Ltd (KIMS) around ₹742.95, with a stop loss at ₹716 and a target…” | Sumeet BagadiaChoice Equity Broking | Krishna Institute of Medical Sciences Ltd | MISS | |
| “Recommends buying Krishna Institute of Medical Sciences (KIMS) with a target price of ₹725. The call is based on the fir…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Krishna Institute of Medical Sciences | PENDING | |
| “Bullish on Krishna Institute of Medical Sciences Ltd, recommending a buy at ₹680 with a target price of ₹800 in three mo…” | Marketsmith India AnalysisMarketsmith India | Krishna Institute of Medical Sciences Ltd | MISS | |
| “Recommends buying KIMS with a target of Rs 704 and a stop loss at Rs 635 for a short-term trading horizon.” | Jaynit VoraIIFL | Krishna Institute of Medical Sciences Ltd | MISS | |
| “Recommends buying Krishna Institute of Medical Sciences Ltd. at ₹662.75, targeting ₹760 in three months with a stop loss…” | Marketsmith India AnalysisMarketsmith India | Krishna Institute of Medical Sciences Ltd. | HIT | |
| “Recommends buying Krishna Institute of Medical Sciences (KIMS) with a target price of ₹725. This call is based on the co…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Krishna Institute of Medical Sciences Limited | HIT | |
| “Recommends buying Krishna Institute of Medical Sciences Ltd (KIMS) at ₹639.65, targeting ₹685 with a stop loss at ₹615. …” | Sumeet BagadiaChoice Equity Broking | Krishna Institute of Medical Sciences Ltd | MISS | |
| “Bullish on Krishna Institute Of Medical Sciences, recommending a buy at ₹595.60 with a target of ₹637 and a stop loss at…” | Sumeet BagadiaChoice Equity Broking | Krishna Institute Of Medical Sciences Ltd | HIT | |
| “Bullish on Krishna Institute Of Medical Sciences, recommending a buy at ₹549.7 with a target of ₹588 and a stop loss at …” | Sumeet BagadiaChoice Equity Broking | Krishna Institute Of Medical Sciences | PENDING | |
| “Recommends buying Krishna Institute of Medical Sciences (KIMS) with a target price of ₹725. The call implies a bullish o…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Krishna Institute of Medical Sciences | PENDING | |
| “Recommends buying Krishna Institute Of Medical Sciences for intraday trading at ₹639.95, targeting ₹685 with a stop loss…” | Sumeet BagadiaChoice Equity Broking | Krishna Institute Of Medical Sciences Ltd | MISS | |
| “Recommends buying Krishna Institute of Medical Sciences (KIMS) with a target price of ₹675. The call implies a bullish o…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Krishna Institute of Medical Sciences | PENDING |
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Krishna Institute of Medical Sciences (KIMS) stock, suggesting buying on dips for short to medium-term trader…” | ETMarkets AnalysisETMarkets.com | Krishna Institute of Medical Sciences | — |
Fundamentals
About Krishna Institute of Medical Sciences Limited
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand in India. The company offers arthroscopy and shoulder, cardiology, cardiothoracic and cardiovascular, organ transplant, medical and surgical gastroenterology, hepatology, orthopaedic, neurology, neurosurgery, nephrology, urology, oncology, pediatric, neonatology, obstetrics and gynaecology, fertility, dental science, emergency and critical care, vascular, rehabilitation and physiotherapy services. It also provides pulmonology, diagnostic and imaging, ophthalmology, ENT, rheumatology and clinical immunology, internal medicine, interventional radiology, diabetology, endocrinology, general surgery, infectious disease, dermatology, thoracic surgery, psychiatry, plastic and reconstructive surgery, transfusion medicine, clinical psychology, anesthesiology, and tele medicine services. In addition, the company operates clinical immunology allergy, bone marrow transplantation, hair transplant, andrology, fertility, alzheimer, arthroscopy, bone and joint, breast, dialysis, female urology, IUI, IVF, joint replacement, kidney health and transplant, ICU, spine, stroke, TAVR/TAVI, hepatobiliary surgery, and trauma centers, as well as pain and wellness clinics. Further, it provides bariatric, thoracic, oral maxillofacial, and endovascular surgery services. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Dr. Abhinay Bollineni
Headquarters
Secunderabad
Website
kimshospitals.comExchange
View on NSE ↗Key stats
Market cap
₹31,103.58 Cr
P/E ratio (TTM)
145.2
Dividend yield
0.00%
EPS (TTM)
₹5.10
Beta (1Y · daily vs NIFTY 50)
0.75
Beta (5Y · monthly vs NIFTY 50)
0.85
Shares float
24.90 Cr
EPS · quarter ended Jun 2026
₹1.04
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,329.94 Cr | ₹1,650.83 Cr | ₹2,197.68 Cr | ₹2,498.14 Cr | ₹3,003.50 Cr | ₹3,904.60 Cr | |
EBITDA | ₹381.05 Cr | ₹536.05 Cr | ₹644.71 Cr | ₹653.48 Cr | ₹824.00 Cr | ₹817.00 Cr |
| ₹201.22 Cr | ₹332.69 Cr | ₹336.32 Cr | ₹310.15 Cr | ₹384.50 Cr | ₹241.40 Cr | |
Diluted EPS | ₹5.24 | ₹8.38 | ₹8.41 | ₹7.75 | ₹9.61 | ₹6.03 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Net income for Mar 2021 could not be checked against the company's own annual report: this page shows ₹201.22 Cr while the annual report gives ₹205.48 Cr (2.1% apart).
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,433.00 Cr | ₹1,904.00 Cr | ₹2,901.00 Cr | ₹3,820.00 Cr | ₹5,689.00 Cr | ₹7,691.00 Cr | |
| ₹316.37 Cr | ₹256.53 Cr | ₹678.17 Cr | ₹1,355.50 Cr | ₹2,561.60 Cr | ₹4,252.90 Cr | |
Stockholders' equity | ₹864.00 Cr | ₹1,387.00 Cr | ₹1,670.00 Cr | ₹1,828.00 Cr | ₹2,138.00 Cr | ₹2,247.00 Cr |
CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹355.97 Cr | ₹520.12 Cr | ₹432.09 Cr | ₹521.09 Cr | ₹581.80 Cr | ₹510.80 Cr | |
Investing cash flow | ₹-354.18 Cr | ₹-606.48 Cr | ₹-546.89 Cr | ₹-752.56 Cr | ₹-1,116.20 Cr | ₹-1,451.70 Cr |
| ₹9.82 Cr | ₹59.87 Cr | ₹19.64 Cr | ₹216.76 Cr | ₹543.10 Cr | ₹940.30 Cr | |
Capital expenditure | ₹-94.00 Cr | ₹-170.00 Cr | ₹-575.00 Cr | ₹-647.00 Cr | ₹-1,009.00 Cr | ₹-1,428.00 Cr |
End cash position | ₹52.13 Cr | ₹25.63 Cr | ₹61.61 Cr | ₹46.89 Cr | ₹56.00 Cr | ₹55.40 Cr |
Debt issued, Debt repaid, Dividends paid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Jun 21 | Sep 21–Sep 23(9Q) | Dec 23–Mar 25(6Q) | Jun 25–Mar 26(4Q) | Jun 26–Jun 26(2Q) |
|---|---|---|---|---|---|
| Promoter | 38.85% | 38.84% | 38.82% | 34.11% | 32.50% |
| Public | 61.15% | 61.16% | 61.18% | 65.89% | 67.50% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Krishna Institute of Medical Sciences Limited | ₹30,681.47 Cr | ₹740.55 | 143.2 | 13.65 | 10.7% | 1.89 | +28.9% | +3.3% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.